Source: Annual Congress 2006 - Lung transplantation: infection, rejection, animal models and more
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. A. Forrest, C. Ward, D. M. Murphy, G. E. Johnson, P. A. Corris (Newcastle upon Tyne, United Kingdom). Serum CA 19-9 in lung allograft recpients. Eur Respir J 2006; 28: Suppl. 50, 4466

Member's Comments

No comment yet.

Related content which might interest you: Ca 19-9 serum levels in patients with end-stage Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 KL-6 in serum as a biomarker for differentiation of chronic allograft dysfuntion in lung transplant. Preliminary results Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside Year: 2016 Lung transplantation of ventilator-dependent patients - analysis of survival and graft function in 27 patients Source: Eur Respir J 2001; 18: Suppl. 33, 179s Year: 2001 Pretransplant factors influencing survival in cystic fibrosis (CF) patients after lung transplantation (LTx) Source: Eur Respir J 2006; 28: Suppl. 50, 724s Year: 2006 Intraabdominal sequestration of the lung and elevated serum levels of CA 19-9: a diagnostic pitfall Source: Eur Respir J 2004; 24: Suppl. 48, 533s Year: 2004 Covid 19 in a lung transplant population Source: Virtual Congress 2021 – Challenging problems in lung transplantation Year: 2021 II-17 upregulation in BAL-fluid during acute rejection after lung transplantation: a 3 months follow-up Source: Eur Respir J 2004; 24: Suppl. 48, 180s Year: 2004 Serum cytokines patterns in lung transplant recipients Source: International Congress 2015 – Pathogenic mechanisms of lung transplant complications: a focus on CLAD Year: 2015 Antibodies against P. aeruginosa exoproteases in BAL from lung transplant recipients Source: Annual Congress 2010 - New clinical and experimental insights in lung transplantation Year: 2010 Elevated lung clearance index (LCI) as an early marker of future bronchiolitis obliterans (BOS) post lung transplant Source: Virtual Congress 2020 – Treatments and biomarkers for lung allograft function and outcome Year: 2020 Bronchial epithelial cell B7-1 and B7-2 mRNA expression after lung transplantation: a role in allograft rejection? Source: Eur Respir J 2002; 20: 165-169 Year: 2002 Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 The diaphragm before and after lung transplant (LT) Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 Breath VOC patterns of lung transplant recipients with and without chronic lung allograft dysfunction (CLAD) Source: International Congress 2017 – Chronic airway disease: markers of disease impact Year: 2017 Exercise capacity in patients with cystic fibrosis at 6 and 12 months after lung transplantation Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018 Azithromycin (Azi) treatment for chronic allograft dysfunction after lung transplantation (LTx) Source: Annual Congress 2003 - Bronchiolitis obliterans: diagnosis and treatment Year: 2003 Late-breaking abstract: Non specific IgG replacement in lung transplantation recipients with low IgG plasma levels: Effects on survival and bronchiolitis obliterans syndrome occurrence Source: Annual Congress 2011 - Immunobiology in the transplanted lung: experimental and clinical evaluations Year: 2011 Survival and lung function in double lung transplant recipients with cystic fibrosis Source: International Congress 2017 – From donor lung selection and organ preservation to lung transplant outcome Year: 2017 12 month follow-up of lung recipients with chronic allograft dysfunction treated with extracorporeal photopheresis (ECP) Source: Annual Congress 2011 - Improving outcomes after lung transplantation Year: 2011 Serum levels of thrombopoietin (TPO) in patients with thrombocytosis due to lung cancer and in essential throbocythaemia (ET) Source: Eur Respir J 2001; 18: Suppl. 33, 234s Year: 2001